Treatment Persistence of Tumour Necrosis Factors And IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis

Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416

In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.

These findings are in agreement with two recent propensity-matched studies involving axSpA patients with previous TNFi exposure. This supports guidelines which recommend individualised care based on patient circumstances and preference. However, head-to-head studies are needed to determine the most appropriate individual treatment sequences and strategies.